Literature DB >> 24529371

Structural insights on the role of antibodies in HIV-1 vaccine and therapy.

Anthony P West1, Louise Scharf2, Johannes F Scheid3, Florian Klein3, Pamela J Bjorkman4, Michel C Nussenzweig5.   

Abstract

Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent HIV-1 infection in humanized mice and macaques when passively transferred. New single-cell-based methods have uncovered many broad and potent donor-derived antibodies, and structural studies have revealed the molecular bases for their activities. The new data suggest why such antibodies are difficult to elicit and inform HIV-1 vaccine development efforts. In addition to protecting against infection, the newly identified antibodies can suppress active infections in mice and macaques, suggesting they could be valuable additions to anti-HIV-1 therapies and to strategies to eradicate HIV-1 infection.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24529371      PMCID: PMC4041625          DOI: 10.1016/j.cell.2014.01.052

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  159 in total

Review 1.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

2.  New templates for HIV-1 antibody-based vaccine design.

Authors:  Quentin J Sattentau; Andrew J McMichael
Journal:  F1000 Biol Rep       Date:  2010-08-09

3.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

4.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency.

Authors:  Anthony P West; Rachel P Galimidi; Christopher P Foglesong; Priyanthi N P Gnanapragasam; Kathryn E Huey-Tubman; Joshua S Klein; Maria D Suzuki; Noreen E Tiangco; Jost Vielmetter; Pamela J Bjorkman
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

6.  Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model.

Authors:  Henning Gruell; Stylianos Bournazos; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig; John Pietzsch
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

7.  Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.

Authors:  Rui Kong; Hui Li; Ivelin Georgiev; Anita Changela; Frederic Bibollet-Ruche; Julie M Decker; Sarah L Rowland-Jones; Assan Jaye; Yongjun Guan; George K Lewis; Johannes P M Langedijk; Beatrice H Hahn; Peter D Kwong; James E Robinson; George M Shaw
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

Review 8.  Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.

Authors:  Daniel E Goldberg; Robert F Siliciano; William R Jacobs
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

9.  Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

Authors:  Sam Hoot; Andrew T McGuire; Kristen W Cohen; Roland K Strong; Lars Hangartner; Florian Klein; Ron Diskin; Johannes F Scheid; D Noah Sather; Dennis R Burton; Leonidas Stamatatos
Journal:  PLoS Pathog       Date:  2013-01-03       Impact factor: 6.823

10.  Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10.

Authors:  Kathryn A K Finton; Kevin Larimore; H Benjamin Larman; Della Friend; Colin Correnti; Peter B Rupert; Stephen J Elledge; Philip D Greenberg; Roland K Strong
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

View more
  192 in total

Review 1.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

2.  Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Authors:  Hong Zhang; Hu Fu; Robert J Luallen; Bingfen Liu; Fang-Hua Lee; Robert W Doms; Yu Geng
Journal:  Vaccine       Date:  2015-08-13       Impact factor: 3.641

3.  HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.

Authors:  Yuge Wang; Pratibha Kapoor; Robert Parks; Aaron Silva-Sanchez; S Munir Alam; Laurent Verkoczy; Hua-Xin Liao; Yingxin Zhuang; Peter Burrows; Michael Levinson; Ada Elgavish; Xiangqin Cui; Barton F Haynes; Harry Schroeder
Journal:  Immunogenetics       Date:  2015-12-19       Impact factor: 2.846

Review 4.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

5.  Natural evolution of broadly neutralizing antibodies.

Authors:  Galit Alter; Dan H Barouch
Journal:  Cell       Date:  2015-04-23       Impact factor: 41.582

6.  Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.

Authors:  Johannes S Gach; Kane J V Mara; Celia C LaBranche; Marit J van Gils; Laura E McCoy; P J Klasse; David C Montefiori; Rogier W Sanders; John P Moore; Donald N Forthal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

7.  Clonal selection in the germinal centre by regulated proliferation and hypermutation.

Authors:  Alexander D Gitlin; Ziv Shulman; Michel C Nussenzweig
Journal:  Nature       Date:  2014-05-04       Impact factor: 49.962

8.  Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Authors:  Ching-Lan Lu; Dariusz K Murakowski; Stylianos Bournazos; Till Schoofs; Debolina Sarkar; Ariel Halper-Stromberg; Joshua A Horwitz; Lilian Nogueira; Jovana Golijanin; Anna Gazumyan; Jeffrey V Ravetch; Marina Caskey; Arup K Chakraborty; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

9.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Authors:  Till Schoofs; Florian Klein; Malte Braunschweig; Edward F Kreider; Anna Feldmann; Lilian Nogueira; Thiago Oliveira; Julio C C Lorenzi; Erica H Parrish; Gerald H Learn; Anthony P West; Pamela J Bjorkman; Sarah J Schlesinger; Michael S Seaman; Julie Czartoski; M Juliana McElrath; Nico Pfeifer; Beatrice H Hahn; Marina Caskey; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

10.  Overlapping hotspots in CDRs are critical sites for V region diversification.

Authors:  Lirong Wei; Richard Chahwan; Shanzhi Wang; Xiaohua Wang; Phuong T Pham; Myron F Goodman; Aviv Bergman; Matthew D Scharff; Thomas MacCarthy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.